Diagnostic Accuracy of a Panel of Bacterial Gene Markers (M3) for Colorectal Advanced Neoplasia (M3-PRO)
A Prospective Cross-sectional Multi-center Study to Assess the Diagnostic Accuracy of a Panel of Bacterial Gene Markers (M3) for Colorectal Advanced Neoplasia
Sponsor: Aster CMI Hospital
This observational or N/A phase trial investigates Colorectal Adenoma and Colorectal Cancer and is currently actively recruiting participants. Aster CMI Hospital leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Aug 2023 — Jul 2024 [monthly]
Recruiting
-
Sep 2022 — Aug 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting
First recorded
Jun 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aster CMI Hospital
- Changi General Hospital
- Chinese University of Hong Kong
- Dr Cipto Mangunkusumo General Hospital
- National Taiwan University Hospital
- Osaka International Cancer Institute
- Oxford University Hospitals NHS Trust
- Phramongkutklao College of Medicine and Hospital
- Sano hospital
- St. Mark's Hospital
- Thingangyun Sanpya General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .